Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting the sarcomere in inherited cardiomyopathies
Sarah Lehman, Claudia Crocini, Leslie A. Leinwand
Nature Reviews Cardiology (2022) Vol. 19, Iss. 6, pp. 353-363
Open Access | Times Cited: 87

Showing 1-25 of 87 citing articles:

Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy
Martin S. Maron, Ahmad Masri, Michael E. Nassif, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 20, pp. 1849-1861
Closed Access | Times Cited: 99
α-myosin heavy chain lactylation maintains sarcomeric structure and function and alleviates the development of heart failure
Naijin Zhang, Ying Zhang, Jiaqi Xu, et al.
Cell Research (2023) Vol. 33, Iss. 9, pp. 679-698
Open Access | Times Cited: 89
Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy
Eugene Braunwald, Sara Saberi, Theodore P. Abraham, et al.
European Heart Journal (2023) Vol. 44, Iss. 44, pp. 4622-4633
Open Access | Times Cited: 58
Physiology of intracellular calcium buffering
David Eisner, Erwin Neher, Holger Taschenberger, et al.
Physiological Reviews (2023) Vol. 103, Iss. 4, pp. 2767-2845
Open Access | Times Cited: 51
Effect of Hepatic Impairment or Renal Impairment on the Pharmacokinetics of Aficamten
Donghong Xu, Justin D. Lutz, Punag Divanji, et al.
Clinical Pharmacokinetics (2025)
Open Access | Times Cited: 1
Danicamtiv Increases Myosin Recruitment and Alters Cross-Bridge Cycling in Cardiac Muscle
Kristina B. Kooiker, Saffie Mohran, Kyrah L. Turner, et al.
Circulation Research (2023) Vol. 133, Iss. 5, pp. 430-443
Open Access | Times Cited: 20
Reassessing the unifying hypothesis for hypercontractility caused by myosin mutations in hypertrophic cardiomyopathy
James A. Spudich, Neha Nandwani, Julien Robert‐Paganin, et al.
The EMBO Journal (2024) Vol. 43, Iss. 19, pp. 4139-4155
Closed Access | Times Cited: 7
Signatures of cysteine oxidation on muscle structural and contractile proteins are associated with physical performance and muscle function in older adults: Study of Muscle, Mobility and Aging (SOMMA)
Nicholas Day, Shane S. Kelly, Li‐Yung Lui, et al.
Aging Cell (2024) Vol. 23, Iss. 6
Open Access | Times Cited: 6
Genetic causes of heart failure with preserved ejection fraction: emerging pharmacological treatments
Iacopo Olivotto, James E. Udelson, Maurizio Pieroni, et al.
European Heart Journal (2022) Vol. 44, Iss. 8, pp. 656-667
Open Access | Times Cited: 23
Emerging Concepts of Mechanisms Controlling Cardiac Tension: Focus on Familial Dilated Cardiomyopathy (DCM) and Sarcomere-Directed Therapies
R. John Solaro, Paul H. Goldspink, Beata M. Wolska
Biomedicines (2024) Vol. 12, Iss. 5, pp. 999-999
Open Access | Times Cited: 5
Functional control of myosin motors in the cardiac cycle
Malcolm Irving
Nature Reviews Cardiology (2024)
Closed Access | Times Cited: 5
Mechanism based therapies enable personalised treatment of hypertrophic cardiomyopathy
Francesca Margara, Yiangos Psaras, Zhinuo Jenny Wang, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 20
Contemporary Therapies and Future Directions in the Management of Hypertrophic Cardiomyopathy
Elizabeth Packard, Alejandro de Feria, Supriya Peshin, et al.
Cardiology and Therapy (2022) Vol. 11, Iss. 4, pp. 491-507
Open Access | Times Cited: 19
Short- and Mid-Term Outcomes of Early Alcohol Septal Ablation Therapy for Patients with Mildly Symptomatic Hypertrophic Obstructive Cardiomyopathy: A Tertiary Center Experience
Veysel Oktay, Şükrü Arslan, Muhammed Heja Geçit, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 5, pp. 1444-1444
Open Access | Times Cited: 4
Tail length and E525K dilated cardiomyopathy mutant alter human β-cardiac myosin super-relaxed state
Sebastian Duno-Miranda, Shane R. Nelson, David V. Rasicci, et al.
The Journal of General Physiology (2024) Vol. 156, Iss. 6
Open Access | Times Cited: 4
Substrate mechanics unveil early structural and functional pathology in iPSC micro-tissue models of hypertrophic cardiomyopathy
Jingxuan Guo, Huanzhu Jiang, David Schuftan, et al.
iScience (2024) Vol. 27, Iss. 6, pp. 109954-109954
Open Access | Times Cited: 4
Hypertrophic cardiomyopathy: current understanding and emerging therapeutics
Jiaqi Dai, Zhu Da, Maurizio Taramasso, et al.
Medicine Plus (2025), pp. 100073-100073
Open Access
The Prognostic Significance of the DBIL/HDLC Ratio in Patients With Dilated Cardiomyopathy
Xinyi Wang, Qiqi Song, Qingqing Zhang, et al.
Cardiovascular Therapeutics (2025) Vol. 2025, Iss. 1
Open Access
Left Ventricle Myocardial Remodeling Following Septal Myectomy in Patients with Hypertrophic Obstructive Cardiomyopathy
Guanyu Lu, Liqi Cao, Jiehao Ou, et al.
Journal of Cardiovascular Magnetic Resonance (2025), pp. 101864-101864
Open Access
Advances in the study and treatment of genetic cardiomyopathies
Victoria N. Parikh, Sharlene M. Day, Neal K. Lakdawala, et al.
Cell (2025) Vol. 188, Iss. 4, pp. 901-918
Closed Access
Velcro-binding by cardiac troponin-I traps tropomyosin on actin in a low-energy relaxed state
Balajee Ramachandran, Michael J. Rynkiewicz, William Lehman
Biochemical and Biophysical Research Communications (2025) Vol. 757, pp. 151595-151595
Closed Access
Metabolic Coordination Structures Contribute to Diabetic Myocardial Dysfunction
Teng Wu, Tongsheng Huang, Huimin Ren, et al.
Circulation Research (2025)
Closed Access
Advances in Therapeutic Targets and Traditional Chinese Medicine for Cardiomyopathy
Shuo Yang, Shuai‐nan Zhang, Xu‐zhao Li
Phytotherapy Research (2025)
Closed Access
Characteristics and pharmacological responsiveness in hiPSC models of inherited cardiomyopathy
Merel Gerritse, Willem B. van Ham, Chris Denning, et al.
Pharmacology & Therapeutics (2025), pp. 108845-108845
Open Access
Mechanistic insights into effects of the cardiac myosin activator omecamtiv mecarbil from mechanokinetic modelling
Alf Månsson
Frontiers in Physiology (2025) Vol. 16
Open Access
Page 1 - Next Page

Scroll to top